Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.49 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.47 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | RXRA | P19793 | 3/20 | 0.49 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
| ▸ | RARG | P13631 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5753150 | 1.00 | NR1H4 (0.60) | NR1H4MCL1RXRARARBRARG | |
| SCHEMBL2772423 | 0.98 | NR1H4 (0.62) | NR1H4MCL1RXRARARBRARG | |
| SCHEMBL29396992 | 0.98 | NR1H4 (0.62) | NR1H4MCL1RXRARARBRARG | |
| Benzoic Acid SCHEMBL27717757 | 0.90 | NR1H4 (0.57) | NR1H4MCL1RXRACA12CA1 | |
| SCHEMBL5289377 | 0.85 | RAB9A (0.55) | NR1H4MCL1CA12CA1CA2 | |
| SCHEMBL25390971 | 0.83 | TSHR (0.62) | RXRARARBRARGCA12CA1 | |
| SCHEMBL2951399 | 0.83 | NR1H4 (0.51) | NR1H4MCL1RXRARARBRARG | |
| SCHEMBL30159253 | 0.83 | NR1H4 (0.51) | NR1H4MCL1RXRARARBRARG | |
| SCHEMBL2772796 | 0.82 | MAPT (0.61) | NR1H4MCL1CA12CA1CA2 | |
| SCHEMBL31327313 | 0.81 | TSHR (0.59) | RXRARARBRARGCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228439-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2024-07-11 | — | — | US | disclosed |
| US-20230226021-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ReproNovo SA (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230097933-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2023-03-30 | — | — | US | disclosed |
| EP-4129979-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ObsEva S.A. (CH) | 2023-02-08 | — | — | EP | disclosed |
| US-11419851-B2 | Oral formulations of pyrrolidine derivatives | ObsEva S.A. (CH) | 2022-08-23 | — | — | US | disclosed |
| US-11312683-B2 | Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists | ObsEva S.A. (CH) | 2022-04-26 | — | — | US | disclosed |
| EP-3252037-B1 | PROCESS FOR THE PREPARATION OF (3Z,5S)-5-(HYDROXYMETHYL)-1-[(2´-METHYL-1,1´-BIPHENYL-4-YL)CARBONYL)PYRROLIDIN-3-ONE O-METHYLOXIME | ObsEva SA (CH) | 2022-03-09 | — | — | EP | disclosed |
| US-20210047266-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2021-02-18 | — | — | US | disclosed |
| EP-3753921-A1 | CRYSTALLINE (3Z,5S)-5-(HYDROXYMETHYL)-1-[(2'-METHYL-1,1'-BIPHENYL-4-YL)CARBONYL]PYRROLIDIN-3-ONE O-METHYLOXIME USEFUL IN METHODS OF TREATING CONDITIONS RELATED TO THE OT-R ACTIVITY | ObsEva S.A. (CH) | 2020-12-23 | — | — | EP | disclosed |
| US-20200281892-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ReproNovo SA (CH) | 2020-09-10 | — | — | US | disclosed |
| WO-2015091365-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ObsEva S.A. (CH) | 2015-06-25 | — | — | WO | disclosed |
| EP-2886107-A1 | Oral formulations of pyrrolydine derivatives | ObsEva S.A. (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-20150164859-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | ReproNovo SA (CH) | 2015-06-18 | — | — | US | disclosed |
| WO-2015036160-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN / VASOPRESSIN V1a RECEPTORS ANTAGONISTS | ObsEva S.A. (CH) | 2015-03-19 | — | — | WO | disclosed |
| US-20150073032-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | ReproNovo SA (CH) | 2015-03-12 | — | — | US | disclosed |
| EP-2845850-A1 | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists | ObsEva S.A. (CH) | 2015-03-11 | — | — | EP | disclosed |
| EP-1725526-B1 | METHOD FOR PREPARING PYRROLIDINE OXIMES | SERONO LAB (CH) | 2007-12-12 | — | — | EP | disclosed |
| US-20070197794-A1 | Method for preparing pyrrolidine oximes | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-08-23 | — | — | US | disclosed |
| EP-1725526-A2 | METHOD FOR PREPARING PYRROLIDINE OXIMES | Applied Research Systems ARS Holding N.V. (AN) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005082848-A2 | METHOD FOR PREPARING PYRROLIDINE OXIMES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281892-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | KDM5A, KDM5C, KDM5B | CA2 3883/4885PPARG 2276/4885EGFR 4884/4885 |
| US-11312683-B2 | Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists | OXTR, AVPR1A, AVPR2 | CA2 2926/4885PPARG 3421/4885EGFR 3641/4885 |
| US-20150073032-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | OXTR, AVPR1A, AVPR2 | CA2 2870/4885PPARG 3966/4885EGFR 3522/4885 |
| US-20150164859-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | KDM5A, KDM5C, KDM5B | CA2 3883/4885PPARG 2276/4885EGFR 4884/4885 |
| US-20230097933-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | OXTR, AVPR1A, AVPR2 | CA2 2681/4885PPARG 3722/4885EGFR 3771/4885 |
| US-20210047266-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | OXTR, AVPR1A, AVPR2 | CA2 2681/4885PPARG 3722/4885EGFR 3771/4885 |
| US-11419851-B2 | Oral formulations of pyrrolidine derivatives | KDM5A, KDM5C, PGF | CA2 3704/4885PPARG 2316/4885EGFR 4884/4885 |
| US-20070197794-A1 | Method for preparing pyrrolidine oximes | PPOX, PGF, OXTR | CA2 2317/4885PPARG 1997/4885EGFR 4845/4885 |
| US-20240228439-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS | AVPR1A, OXTR, AVPR2 | CA2 2838/4885PPARG 3941/4885EGFR 3727/4885 |
| US-20230226021-A1 | ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES | KDM5A, KDM5C, KDM5B | CA2 3883/4885PPARG 2276/4885EGFR 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.